Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Inhibrx Biosciences Inc

INBX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$122.26

▼ -2.17%

Market Cap $1.80B · Vol 52.93K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.80B

Small Cap

Div Yield

N/A

EPS Growth

-13.18%

YoY

RSI (14)

82.64

Momentum

Beta

N/A

vs Market

52W High

$155.29

19.52% below

52W Low

$26.19

377.17% above

Volume

52.93K

Avg 77.63K

P/B

144.08

Price-to-book

ROE

N/A

Return on equity

Free Float

68.10%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Inhibrx Biosciences Inc (INBX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INBX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.35%

+47.80%

+28.40%

+64.48%

YTD

+54.76%

+339.78%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$1.30M
Net Income	$-140,055,000.00
Revenue Growth (YoY)	-100.00%
Gross Margin	100.00%
Operating Margin	-10,386.54%
Net Profit Margin	-10,773.46%
ROE	N/A
ROA · ROIC	-85.60% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	941.13
P/B	144.08
P/FCF	N/A
EPS Growth	-13.18%
Outstanding Shares	14.72M

Technical Indicators

50-Day SMA	$96.68
200-Day SMA	$88.74
RSI (14)	82.64
Beta	N/A
52-Week High	$155.29
52-Week Low	$26.19

Volume Today	52.93K
Avg Daily Volume (30D)	77.63K
Relative Volume	0.68x
Volatility (10D)	77.87
Volatility (30D)	69.33
Free Float	68.10%

Analyst Consensus

BUY

Current Price $122.26

Mean Target $266.67

52W Low$26.19 52W High$155.29

Current

Target

$26.19 $155.29

Current Analyst target

+118.11% upside potential · 2 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00P80N9V6

ISINUS45720N1037

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -0.24% RVMD Revolution Medicines Inc +0.78% ONC BeOne Medicines AG +0.25% 068270.KS Celltrion Inc +0.43% ABVX Abivax SA +2.66%

Company Profile

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is an engineered tetravalent single domain antibody (sdAb)-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death. INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 that provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death. INBRX-106 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors.